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Abstract The synthesis of two marine natural products containing a 3-
alkylidene-6-arylidene-2,5-diketopiperazine scaffold by employing two 
consecutive aldol condensations starting with 1,4-diacetyl-2,5-
diketopiperazine is reported. The target compounds contain a phenol or an 
imidazole group as aryl substituents, respectively, and suitable conditions for 
the aldol condensation of 1-acyl-3-alkylidene-2,5-diketopiperazine with the 
required functionalized aromatic aldehydes were developed. Provided the 
optimal base was used, introduction of the phenol group did not require use 
of a protecting group. Boc-protection was beneficial for introduction of the 
imidazole group, and conditions for carrying out the aldol condensation and 
Boc-deprotection in one step was identified. Additionally, the 
stereochemistry of the target compounds was confirmed by NMR analysis.	
Key words 2,5-diketopiperazine; natural product; total synthesis; aldol 
condensation; alkylidene; arylidene. 
 
2,5-Diketopiperazine	(DKPs),	which	formally	consists	of	a	head-
to-tail	 cyclized	 dipeptide,	 is	 a	 privileged	 scaffold	 found	 in	
numerous	 natural	 products	 displaying	 a	 wide	 range	 of	
bioactivities,	 e.g.	 antibacterial,	 antiviral,	 anticancer,	 anti-
inflammatory,	 antioxidant	 and	 antibiofouling,	 as	 well	 as	 in	
several	approved	drugs,	e.g.	the	PDE5	inhibitor	tadalafil	and	the	
oxytocin	 receptor	 antagonists	 retosiban	 and	 epelsiban.2	 The	
DKP	 ring	 can	 be	 the	 main	 structural	 feature	 of	 smaller	
compounds	 e.g.	 (–)-phenylahistin3	 (1)	 or	 part	 of	 a	 complex	
structure	 e.g.	 the	 spiro-annulated	 brevianamide	 A	 (2)	 (Figure	
1).	 Unsaturated	DKPs	 such	 as	 3-dehydro-	 and	 3,6-didehydro-
2,5-DKPs	 formally	 derived	 from	 dehydroamino	 acids	 have	
attracted	 attention	 as	 anticancer	 agents	 e.g.	 the	 tubulin	
polymerisation	 inhibitor	 plinabulin4	 (now	 in	 Phase	 3	 clinical	
trials	 for	 treatment	 of	 non-small	 cell	 lung	 cancer)	 and	 the	
plasmogen	activator	inhibitor	XR5967.5		
Due	 to	 the	 potential	 pharmaceutical	 interest	 of	 3,6-bis-
arylidene-DKPs,	 synthetic	 methods	 for	 their	 preparation	 are	
well	 established.2a,	 2c,	 6	 However,	 few	 examples	 for	 the	 prepa-
ration	of	3-alkylidene-6-arylidene-DKPs	are	known.7	Reported	
methods	 for	 the	 formation	of	3-alkylidene-DKPs	are	 based	on	
the	 reaction	 of	 alkyl	 aldehydes	 with	 a	 preformed	 DKP	 via	 a	
condensation,7c-h,	 8	 a	 Wittig	 reaction8g, 9 or	 cyclisation	 of	 di-
peptides	 containing	 a	 dehydroaminoacid.7b,	 7c	 	 Among	 these	
methods,	 condensation	 reactions	 are	most	 frequently	 utilized	
for	 the	 preparation	 of	 3-alkylidene-6-arylidene-DKPs.7a,c-h	
However	with	one	exception,7a	condensation	reactions	towards	





we	 became	 interested	 in	 DKP-based	 compounds	 and	 the	
synthesis	of	the	natural	3-alkylidene-6-arylidene-DKPs	3	and	4	
(Figure	 1).10	 The	 compounds	 are	 related	 to	 the	 reported	
albonoursin.7b,	7d-g,	11	However,	instead	of	having	a	non-reactive	
phenyl	 substituent,	 natural	 products	3	 and	4	 contain	 either	 a	
phenol	 or	 an	 imidazole	 group,	 respectively.	 Our	 synthetic	
investigations	 show	 that	 two	 subsequent	 condensation	
reactions	can	give	access	to	compounds	3	and	4	from	the	same	
starting	 material.	 Base-reactive	 aromatic	 aldehydes	 can	 be	
employed,	 provided	 the	 appropriate	 conditions	 are	 used.	 In	
addition,	 access	 to	4	 allowed	 for	 confirmation	of	 the	 reported	
stereochemistry	by	NMR	analysis.	




Figure 1. Biologically active 2,5-diketopiperazines 
5	as	starting	material	(Scheme	1).	In	accordance	with	previous	
reports,7d	 successful	 introduction	 of	 an	 alkylidene	 side	 chain	
was	not	efficient	once	an	arylidene	side	chain	had	been	installed.	
However,	by	first	reacting	5	with	isobutyraldehyde	(Scheme	1)	
and	 then	 treating	 the	 resulting	 1-acetyl-3-alkylidene-DKP	 6	
with	 either	 4-hydroxybenzaldehyde	 (Scheme	 1)	 or	 protected	
imidazole-5-carbaldehyde	 (Scheme	 2)	 the	 natural	 products	 3	
and	4	were	successfully	obtained.	
 
Scheme 1. Successful route to natural product 3. 
The	 condensation	 of	 5	 with	 isobutyraldehyde	 was	 first	
attempted	 using	 the	 conditions	 reported	 by	 Folkes	 and	 co-
workers	 for	 condensations	 with	 aromatic	 aldehydes.12	 Using	
Cs2CO3	 in	degassed	DMF	at	 room	 temperature	gave	6	 in	21%	
yield	after	18	h.	 Increasing	 the	 reaction	 temperature	 to	80	 °C	
improved	 the	 yield	 to	 42%.	 We	 initially	 used	 a	 1:1:1	 ratio	
between	 DKP	 5,	 Cs2CO3	 and	 aldehyde,	 and	 the	 work-up	
consisted	of	adding	crushed	ice	to	the	reaction	mixture	and	then	
isolating	 the	 precipitated	 product	 in	 pure	 form	 by	 filtration.	
Further	attempts	to	improve	the	reaction	by	using	an	excess	of	
base	 or	 aldehyde	 necessitated	 chromatographic	 purification	
due	to	the	more	complex	crude	products	this	gave,	and	did	not	
result	in	improved	yields.	
We	 then	 turned	 to	 the	 conditions	 described	 by	 Gallina7d	
employing	 t-BuOK	 as	 base	 at	 room	 temperature	 (Scheme	 1).	
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gave	mono-substituted	DKP	613	in	up	to	66%	yield	(Scheme	2).	
A	 larger	excess	of	 isobutyraldehyde	gave	the	product	 in	 lower	
purity	and	failed	to	provide	6	in	higher	yield.	
 
Scheme 2. Synthesis of natural product 4. 
One	 caveat	 of	 this	 approach	 was	 the	 necessity	 of	 a	
chromatographic	step	in	the	work-up	protocol.	The	preparation	
of	6	has	been	carried	out	several	times	using	t-BuOK	as	base,	and	
in	 some	cases,	 evaporation	of	 the	 solvent	 following	extraction	
afforded	pure	6	after	washing	with	distilled	water,	however,	on	
other	instances	flash	chromatographic	purification	of	the	crude	







carbaldehyde	 with	 or	 without	 N-Boc	 protection	 (Scheme	 2)	






hydroxybenzaldehyde	 under	 the	 same	 reaction	 conditions,7a	
which	were	solved	by	re-acetylating	the	free	N-H	of	6.	
Reactions	 of	 6	 with	 unprotected	 imidazole-5-carbaldehyde	
using	 either	 either	 Cs2CO3	 or	 t-BuOK	 at	 80	 °C	 resulted	 in	 the	
formation	of	a	complex	mixture	of	products,	4	being	one	of	them	
albeit	 in	 modest	 amounts.	 The	 flash	 chromatographic	
purification	 proved	 to	 be	 inefficient	with	 several	 unidentified	
products	co-eluting	with	the	desired	product.	We	then	switched	
to	using	 the	N-Boc-protected	 imidazole-5-carbaldehyde.	Using	
1.2	 equiv.	 of	 t-BuOK	 as	 base,	 a	 much	 cleaner	 crude	 product,	
which	also	was	amenable	to	flash	chromatographic	purification	
was	obtained	 (Scheme	 2).	We	 found	 that	 the	N-Boc-protected	





415	 (instead	of	7)	was	 isolated	 in	59%	yield,	 thus	avoiding	an	
additional	deprotection	 step.	Use	of	 a	 larger	 excess	of	 t-BuOK	
did	not	improve	the	outcome	of	the	reaction.	Instead	significant	
deacetylation	of	6	was	observed.16	Unfortunately,	use	of	Cs2CO3	
in	 the	 condensation	 of	 5	 with	 N-Boc-protected	 imidazole-5-
carbaldehyde	was	largely	unsuccessful	and	gave	7	in	a	mere	5%	
yield	(data	not	shown).	





aldol	 condensation	of	8	resulted	 in	 the	 formation	of	both	 (E)-	
and	(Z)-double	bond	isomers	in	an	estimated	9:1	ratio	between	




Scheme 3. Attempted synthesis using N-Boc protected DKPs. 
The	 second	 condensation	 step	 was	 attempted	 with	 4-
hydroxybenzaldehyde	(using	either	1.2	or	2.5	equiv.	t-BuOK	as	






bonds	 in	 4	 were	 suggested	 to	 be	 of	 (Z)-configuration.9	 It	 is	
reasonable	 to	 anticipate	 that	 our	 synthetic	 product	 is	 the	
(3Z,6Z)-isomer	 of	 4	 based	 on	 the	 high	 (Z)-stereoselectivity	




corresponding	 distances	 through	 space	 for	 the	 (3Z)-	 and	 the	
(3E)-isomer	 were	 compared	 based	 on	 3D	 models	 from	
molecular	 mechanic	 simulations	 (Figure	 2).	 For	 the	 (3Z)-
rotamers,	 the	 distances	 were	 estimated	 to	 3.7,	 2.4/5.0	 and	
5.4/4.0	Å,	respectively	(see	SI),	which	was	in	agreement	with	the	
observed	NOE	contacts.	 In	contrast,	 for	the	(3E)-rotamers,	 the	























4: R = H
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Figure 2. NOE contacts and distances (Å) for stereoisomers of 4. 
In	 conclusion,	 the	 syntheses	of	 the	marine	natural	products	3	
and	4	were	conducted	in	two	steps	with	an	overall	yield	of	28%	
and	 39%,	 respectively.	 We	 have	 shown	 that	 a	 double	
condensation	 strategy	 is	 applicable	 to	 the	 synthesis	 of	 3-
alkylidene-6-arylidene	 DKPs	 containing	 functionalized	 aryl	
substituents.	 Efficient	 introduction	 of	 the	 imidazole	 group	
required	 Boc-protection,	 however,	 we	 have	 identified	
conditions	 that	 allows	 for	 aldol	 condensation	 and	 Boc-
deprotection	to	be	carried	out	in	one	step.	Our	results	indicate	
that	the	outcome	of	the	second	condensation	is	more	sensitive	
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temperature	 before	 the	 reaction	 mixture	 was	 partitioned	
between	 ethyl	 acetate	 (15	mL)	 and	 a	 saturated	 NH4Cl-solution	
(15	 mL).	 The	 aqueous	 layer	 was	 extracted	 further	 with	 ethyl	
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dried	 over	 anhydrous	 Na2SO4	 and	 evaporated	 in	 vacuo	 until	
approx	 ~1	 mL	 of	 an	 oily	 residue	 remained	 (contains	 residual	
DMF).	 The	 oily	 residue	 was	 purified	 by	 flash	 column	
chromatography	 (EtOAc)	 to	 give	 the	 title	 compound	 as	 a	 pale	
yellow	 amorphous	 solid	 (116	 mg,	 59%).	 Rf	 =	 0.58	 (EtOAc).	




0.97	(d,	 J	=	 6.5	Hz,	6H);	 13C	NMR	(126	MHz,	DMSO-d6)	δ	157.3,	
156.2,	136.5,	136.5,	125.4,	124.9,	124.7,	119.2,	104.4,	23.8,	22.2.	
HRMS	 (ESI):	m/z	 [M-H]-	 calcd	 for	 C12H13N4O2:	 245.1044;	 found	
245.1041.	
(16) Use	of	1.8	equiv.	of	t-BuOK	gave	an	estimated	1:0.6	ratio	of	4	and	
deacetylated	6	in	the	crude	product.	
